Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Hermiller

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Circulation. Cardiovascular Interventions|June 7, 2021
Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk TrialSuzanne V Arnold, George Petrossian, Michael J Reardon, et al.
Circulation|April 14, 2004
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trialGregg W Stone, Stephen G Ellis, David A Cox, et al.
American Heart Journal|December 11, 2017
Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trialSuzanne J Baron, Suzanne V Arnold, Matthew R Reynolds, et al.
The New England Journal of Medicine|January 16, 2004
A polymer-based, paclitaxel-eluting stent in patients with coronary artery diseaseGregg W Stone, Stephen G Ellis, David A Cox, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 20, 2008
Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) GroupBruce R Brodie, Thomas Stuckey, William Downey, et al.
JACC. Cardiovascular Interventions|November 21, 2009
Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) groupBruce R Brodie, Hadley Wilson, Thomas Stuckey, et al.
Circulation|August 30, 2021
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled TrialDhanunjaya Lakkireddy, David Thaler, Christopher R Ellis, et al.
Journal of the American College of Cardiology|April 16, 2011
The acute hemodynamic effects of MitraClip therapyRobert J Siegel, Simon Biner, Asim M Rafique, et al.
The American Journal of Cardiology|February 22, 2005
Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft interventionAravind Swaminathan, Gregg W Stone, Campbell Rogers, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) groupBruce R Brodie, Thomas Stuckey, William Downey, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Circulation. Cardiovascular Interventions|June 7, 2021
Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk TrialSuzanne V Arnold, George Petrossian, Michael J Reardon, et al.
Circulation|April 14, 2004
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trialGregg W Stone, Stephen G Ellis, David A Cox, et al.
American Heart Journal|December 11, 2017
Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trialSuzanne J Baron, Suzanne V Arnold, Matthew R Reynolds, et al.
The New England Journal of Medicine|January 16, 2004
A polymer-based, paclitaxel-eluting stent in patients with coronary artery diseaseGregg W Stone, Stephen G Ellis, David A Cox, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 20, 2008
Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) GroupBruce R Brodie, Thomas Stuckey, William Downey, et al.
JACC. Cardiovascular Interventions|November 21, 2009
Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) groupBruce R Brodie, Hadley Wilson, Thomas Stuckey, et al.
Circulation|August 30, 2021
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled TrialDhanunjaya Lakkireddy, David Thaler, Christopher R Ellis, et al.
Journal of the American College of Cardiology|April 16, 2011
The acute hemodynamic effects of MitraClip therapyRobert J Siegel, Simon Biner, Asim M Rafique, et al.
The American Journal of Cardiology|February 22, 2005
Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft interventionAravind Swaminathan, Gregg W Stone, Campbell Rogers, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) groupBruce R Brodie, Thomas Stuckey, William Downey, et al.
Pageof 9